Taysha Gene Therapies, Inc. Retained Earnings
Taysha Gene Therapies, Inc. (TSHA) had Retained Earnings of -$800.35 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-11
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$800.35M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$753.71M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$711.30M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$683.45M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$800.35M 10-Q · filed 2026-08-11 |
| 2026-03-31 | -$753.71M 10-Q · filed 2026-05-06 |
| 2025-12-31 | -$711.30M 10-Q · filed 2026-08-11 |
| 2025-09-30 | -$683.45M 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$650.72M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$623.83M 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$602.30M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$583.52M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$558.00M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$537.07M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$513.01M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$560.75M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$443.66M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$419.06M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$401.44M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$345.94M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$319.63M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$285.76M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$235.65M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$185.26M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$134.08M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$93.15M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$61.13M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$42.81M 10-Q · filed 2020-11-12 |
| 2019-12-31 | -$1.11M 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |